WJ35435

Overview

WJ35435 is a dual-targeted anticancer hybrid that induces anti- HDAC (in particular HDAC1 and HDAC6 ) and anti- topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis . WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti- HDAC effect. WJ35435 is promising for research of cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Topoisomerase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-117688
• CAS No.: 1620054-84-3
• Molecular Formula: C20H21N3O3
• Molecular Weight: 351.40
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source